1Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults[ J]. Am J Gastroenterol,2001,96( 3 ) :635-643.
2Panaccione R, Ferraz JG, Beck P. Advances in medical therapy of inflammatory bowel disease [ J ]. Curr Opin Pharmacol, 2005,5 (6) :566-572.
3Travis SPL, Stange EF, Le'mann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease : current management [ J ]. Gut ,2006,55 ( Suppl Ⅰ) :i16-i35.
4Towers R, Naftali T, Gabay G, et al. High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance [ J ]. Clin Exp Immunol,2005,141 ( 2 ) : 357-362.
5Feagan BG, Loftus EV, Kamm MA ,et al. Impact of steroid discontinuation on healthcare resource utilization in Crohn's disease[J]. Am J Gastrcenterol,2007,102 : S445-446.
6Colombel JF, Kamm MA, Schwartz D, et al. Sustainability of adalimumab in fistula healing and response :2 year data from CHARM and 12-month open-label extension follow-up study [ J ]. Am J Gastroenterol, 2007,102 : S497 -498.
7Sachar DB. Indications for Surgery in Crohn's Disease[J]. Am J Gastroenterol,2007,102 : S76-S78.
9Wright RA, Adler EC. Peripheral parenteral nutrition is no better than enteral nutrition in acute exacerbation of Crohn's disease: a prospective trial[J]. J Clin Gastroenterol,1990,12(4) :396-399.
10Gassull MA, Fernandez-Banares F, Cabre E ,et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial [ J ]. Gut, 2002,51 ( 2 ) : 164 -168.
